Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$131.18 ▲ +1.15
(+0.88%)
MKT CAP: $14.89B • VOL: 1.88M
52W L $61 52W H $134
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$110
MEDIAN
$147
MEAN
$150
HIGH
$178
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE HALO TAPE
HALO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $158.73 | $150.86 | 2025-02-14 | $119.37 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $165.29 | $154.79 | 2025-02-06 | $123.31 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $149.55 | $144.30 | 2025-01-29 | $125.93 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $133.80 | — | 2025-01-17 | $128.56 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $115.44 | $124.62 | 2025-01-09 | $116.75 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $156.10 | $136.43 | 2024-12-18 | $114.13 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $127.24 | $132.49 | 2024-12-04 | $122.00 | -4.3% | 48% | C |